Hyperphosphatemia
📧 Sign up to get email alerts when something new happens for Hyperphosphatemia.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2020-02-04EMA Lapsed: Fexeric (ferric citrate coordination complex) — Akebia Europe Limited
EMA has lapsed the marketing authorization for Fexeric (ferric citrate coordination complex) in Europe, with hyperphosphatemia and renal dia…
-
EMA withdrawal · 2018-03-27EMA Lapsed: Tasermity (sevelamer hydrochloride) — Genzyme Europe BV
EMA has lapsed the marketing authorization for Tasermity (sevelamer hydrochloride) by Genzyme Europe BV for hyperphosphatemia and renal dial…
-
EMA withdrawal · 2015-04-01EMA Withdrawn: BindRen (colestilan) — Mitsubishi Pharma Europe Ltd
The EMA has withdrawn BindRen (colestilan) from the market in Europe.
-
CLINICAL_TRIALS withdrawal · 2012-09-26Clinical Trial Update: Effect of Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure (CKD) [NA]
Clinical trial evaluating the effect of sevelamer on glucose tolerance and insulin sensitivity in chronic kidney disease was withdrawn.